Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion type Assertion NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_head.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion description "[In in vitro experiments using ATC SW1736 cells, the expression levels of OCT-4, NANOG, and ABCG2 and the sensitivity to either cisplatin or doxorubicin were evaluated after silencing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_provenance.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion evidence source_evidence_literature NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_provenance.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion SIO_000772 23301671 NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_provenance.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion wasDerivedFrom befree-20150227 NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_provenance.
- NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_assertion wasGeneratedBy ECO_0000203 NP636032.RAbe9GrD9MgYx_oO8dE0bYglR6Fe9URKtPKiI1DckQcGY130_provenance.